1NE0 Stock Chart & Stats
€4.68
-€0.18(-3.70%)
At close: 4:00 PM EDT
€4.68
-€0.18(-3.70%)
Day’s Range― - ―
52-Week Range€2.78 - €7.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€77.76M
Enterprise Value€93.55
Total Cash (Recent Filing)€11.20M
Total Debt (Recent Filing)€1.81M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 09, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding17,178,785
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.89Price Target Upside196.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)€22.08M
Bulls Say, Bears Say
Bulls Say
High Gross Product MarginsSustained very high gross margins at the product level indicate attractive unit economics and pricing power for YCANTH. This structural margin cushion supports reinvestment in commercial expansion and R&D while providing a buffer against pricing pressure and distribution inefficiencies over the next several quarters.
YCANTH Commercial MomentumAccelerating unit volumes and sequential revenue growth reflect improving prescriber adoption and channel traction for an in‑office dermatology therapy. Durable demand growth increases recurring clinic usage, strengthens payer familiarity, and supports a path to scale commercial operations over the next 2–6 months.
Partnership Funding For DevelopmentSubstantial external funding from Torii for the Phase III program materially de‑risks near‑term development financing and accelerates enrollment. This structural funding reduces immediate capital needs, preserves management focus on commercialization, and improves probability of timely regulatory milestones.
Bears Say
Ongoing Cash Burn And LossesConsistent multi‑period operating cash outflows and large TTM losses indicate the company remains cash‑consuming. Persistent negative cash flow necessitates external financing, constrains strategic optionality, and elevates execution risk until sustained profitability or durable external funding is secured.
Weakened Equity CushionA sharp decline in shareholders' equity reduces the balance‑sheet buffer against continued losses and increases sensitivity to adverse outcomes. With limited internal capital, the firm faces higher probability of dilutive or costly financing if revenue and margin improvements do not materialize within the projected runway.
Revenue Volatility From Lumpy MilestonesMaterial year‑over‑year revenue swings driven by one‑time collaboration milestones make top‑line predictability weak for planning and investment. Such lumpy revenue complicates forecasting, increases reliance on milestone timing, and undermines steady cash generation from core product sales alone.
Verrica Pharmaceuticals News
1NE0 FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €2.78 and its highest was €7.60 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is €77.76M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Nov 09, 2026 which is in 92 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -€0.536 earnings per share for the quarter, missing the consensus estimate of -€0.336 by -€0.201.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.35.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.536 in its last earnings report, missing expectations of -€0.336. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1NE0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.89 (196.71% Upside)
€13.89 (196.71% Upside)
Blogger Sentiment
Neutral
DE:1NE0 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.04%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
1NE0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of clear commercial momentum for YCANTH (robust unit growth, quarter-over-quarter revenue gains, new international distribution, and strong trial progress) and encouraging clinical signals (VP-315 Phase II abscopal effects and active Phase III enrollment for common warts). Offsetting these positives are sizable year-over-year revenue decline driven by last year’s one-time milestone, substantial GAAP and non-GAAP losses, materially higher R&D and SG&A expense, a legal settlement charge, and a relatively modest cash balance that makes the company reliant on a conditional credit facility. Management’s nondilutive financing and Torii’s substantial trial funding materially de-risk near-term liquidity and program funding, but financial outcomes remain contingent on milestone achievement, careful draw decisions, and successful trial readouts.View all DE:1NE0 earnings summaries1NE0 Stock 12 Month Forecast
Average Price Target
€13.89
▲(196.71% Upside)